XDH and gout: However, a retrospective cohort study that included 1565 gout patients from the Netherlands reported no gender differences in the response to ULT with the XOR inhibitor allopurinol (255 women and 1045 men) or the uricosuric drug benzbromarone (60 women and 205 men) after correction for confounding factors [26].